Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 2
1968 1
1975 1
1976 1
1977 3
1978 1
1979 1
1981 1
1982 1
1990 2
1991 2
1992 5
1993 5
1994 3
1995 3
1996 7
1997 4
1998 4
1999 9
2000 1
2001 5
2002 1
2003 3
2004 4
2005 10
2006 9
2007 8
2008 10
2009 11
2010 9
2011 15
2012 6
2013 9
2014 13
2015 12
2016 8
2017 9
2018 8
2019 11
2020 6
2021 8
2022 8
2023 13
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Planchard D, et al. Among authors: maurel jm. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937763 Clinical Trial.
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Lucien Geater S, Maurel JM, Rojas C, Takahashi T, Havel L, Shepherd FA, Tanaka K, Ghiorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Chaudhry AA, Yang JC. Jänne PA, et al. Among authors: maurel jm. J Clin Oncol. 2024 Mar 1;42(7):808-820. doi: 10.1200/JCO.23.02219. Epub 2023 Dec 2. J Clin Oncol. 2024. PMID: 38042525 Free PMC article. Clinical Trial.
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Van Cutsem E, et al. Among authors: maurel j. J Clin Oncol. 2007 May 1;25(13):1658-64. doi: 10.1200/JCO.2006.08.1620. J Clin Oncol. 2007. PMID: 17470858 Clinical Trial.
The Tumor Microenvironment in Colorectal Cancer Therapy.
Pedrosa L, Esposito F, Thomson TM, Maurel J. Pedrosa L, et al. Among authors: maurel j. Cancers (Basel). 2019 Aug 14;11(8):1172. doi: 10.3390/cancers11081172. Cancers (Basel). 2019. PMID: 31416205 Free PMC article. Review.
Clinical relevance of colorectal cancer molecular subtypes.
Rodriguez-Salas N, Dominguez G, Barderas R, Mendiola M, García-Albéniz X, Maurel J, Batlle JF. Rodriguez-Salas N, et al. Among authors: maurel j. Crit Rev Oncol Hematol. 2017 Jan;109:9-19. doi: 10.1016/j.critrevonc.2016.11.007. Epub 2016 Nov 23. Crit Rev Oncol Hematol. 2017. PMID: 28010901 Review.
The controversy of neoadjuvant therapy in rectal cancer.
Maurel J, Pedrosa L, Camps J. Maurel J, et al. Cir Esp (Engl Ed). 2019 Aug-Sep;97(7):361-363. doi: 10.1016/j.ciresp.2019.01.004. Epub 2019 Feb 14. Cir Esp (Engl Ed). 2019. PMID: 30773234 English, Spanish. No abstract available.
Time Interval Between the End of Neoadjuvant Therapy and Elective Resection of Locally Advanced Rectal Cancer in the CRONOS Study.
Guzmán Y, Ríos J, Paredes J, Domínguez P, Maurel J, González-Abós C, Otero-Piñeiro A, Almenara R, Ladra M, Prada B, Pascual M, Guerrero MA, García-Granero Á, Fernández L, Ochogavia-Seguí A, Gamundi-Cuesta M, González-Argente FX, Pons LV, Centeno A, Arrayás Á, de Miguel A, Gil-Gómez E, Gómez B, Martínez JG, Lacy AM, de Lacy FB. Guzmán Y, et al. Among authors: maurel j. JAMA Surg. 2023 Sep 1;158(9):910-919. doi: 10.1001/jamasurg.2023.2521. JAMA Surg. 2023. PMID: 37436726
The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas.
Sánchez-Tilló E, Pedrosa L, Vila I, Chen Y, Győrffy B, Sánchez-Moral L, Siles L, Lozano JJ, Esteve-Codina A, Darling DS, Cuatrecasas M, Castells A, Maurel J, Postigo A. Sánchez-Tilló E, et al. Among authors: maurel j. JCI Insight. 2023 Oct 23;8(20):e164629. doi: 10.1172/jci.insight.164629. JCI Insight. 2023. PMID: 37870961 Free PMC article.
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.
Pesántez D, Ten Hoorn S, Machado I, García-Albéniz X, Rodríguez-Salas N, Heredia-Soto V, Viñal D, Pericay C, García-Carbonero R, Losa F, Alonso V, Vera R, Feliu Batlle J, Gallego J, Salud A, Nogué M, Layos L, Montagut C, Capdevila J, Vermeulen L, Maurel J, Fernandez-Martos C. Pesántez D, et al. Among authors: maurel j. J Natl Cancer Inst. 2023 Dec 6;115(12):1497-1505. doi: 10.1093/jnci/djad120. J Natl Cancer Inst. 2023. PMID: 37405857 Clinical Trial.
231 results